EU CHMP positive on new aliskiren combination
This article was originally published in Scrip
Executive Summary
Novartis's aliskiren franchise has been given another boost with a CHMP positive opinion for Rasilamlo, a combination of the renin inhibitor with the calcium channel blocker amlodipine.